Logo do repositório

Biopharmaceutical and nanotoxicological aspects of cyclodextrins for non-invasive topical treatments: A critical review

dc.contributor.authorRiccio, Bruno Vincenzo Fiod [UNESP]
dc.contributor.authorMeneguin, Andréia Bagliotti [UNESP]
dc.contributor.authorBaveloni, Franciele Garcia [UNESP]
dc.contributor.authorde Antoni, Juliana Aenishanslin
dc.contributor.authorRobusti, Leda Maria Gorla [UNESP]
dc.contributor.authorGremião, Maria Palmira Daflon [UNESP]
dc.contributor.authorFerrari, Priscileila Colerato
dc.contributor.authorChorilli, Marlus [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionUniversidade Estadual de Ponta Grossa (UEPG)
dc.date.accessioned2023-07-29T13:39:33Z
dc.date.available2023-07-29T13:39:33Z
dc.date.issued2022-01-01
dc.description.abstractCyclodextrins are nanometric cyclic oligosaccharides with amphiphilic characteristics that increase the stability of drugs in pharmaceutical forms and bioavailability, in addition to protecting them against oxidation and UV radiation. Some of their characteristics are low toxicity, biodegradability, and biocompatibility. They are divided into α-, β-, and γ-cyclodextrins, each with its own particularities. They can undergo surface modifications to improve their performances. Furthermore, their drug inclusion complexes can be made by various methods, including lyophilization, spray drying, magnetic stirring, kneading, and others. Cyclodextrins can solve several problems in drug stability when incorporated into dosage forms (including tablets, gels, films, nanoparticles, and suppositories) and allow better topical biological effects of drugs at administration sites such as skin, eyeballs, and oral, nasal, vaginal, and rectal cavities. However, as they are nanostructured systems and some of them can cause mild toxicity depending on the application site, they must be evaluated for their nanotoxicology and nanosafety aspects. Moreover, there is evidence that they can cause severe ototoxicity, killing cells from the ear canal even when applied by other administration routes. Therefore, they should be avoided in otologic administration and should have their permeation/penetration profiles and the in vivo hearing system integrity evaluated to certify that they will be safe and will not cause hearing loss.en
dc.description.affiliationDepartment of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.affiliationDepartment of Pharmaceutical Sciences Ponta Grossa State University (UEPG)
dc.description.affiliationUnespDepartment of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.identifierhttp://dx.doi.org/10.1002/jat.4429
dc.identifier.citationJournal of Applied Toxicology.
dc.identifier.doi10.1002/jat.4429
dc.identifier.issn1099-1263
dc.identifier.issn0260-437X
dc.identifier.scopus2-s2.0-85147039577
dc.identifier.urihttp://hdl.handle.net/11449/248281
dc.language.isoeng
dc.relation.ispartofJournal of Applied Toxicology
dc.sourceScopus
dc.subjectdrug dosages
dc.subjectnanotoxicology
dc.subjectototoxicity
dc.subjectstability
dc.subjectstructural modifications
dc.titleBiopharmaceutical and nanotoxicological aspects of cyclodextrins for non-invasive topical treatments: A critical reviewen
dc.typeResenhapt
dspace.entity.typePublication
relation.isDepartmentOfPublicatione214da1b-9929-4ae9-b8fd-655e9bfeda4b
relation.isDepartmentOfPublication.latestForDiscoverye214da1b-9929-4ae9-b8fd-655e9bfeda4b
unesp.author.orcid0000-0002-2370-0662[1]
unesp.departmentFármacos e Medicamentos - FCFpt

Arquivos